ASX-listed Proteomics International Laboratories is gearing up for the global rollout of its revolutionary blood test for oesophageal cancer, PromarkerEso, by assembling a powerhouse clinical advisory board stacked with some of the world’s leading specialists in gastroenterology and cancer diagnostics.
The Perth-based precision diagnostics trailblazer has assembled the high-powered group to steer its commercialisation push, as the company readies to soon launch PromarkerEso in Australia and then beyond.
